JP2001523729A5 - - Google Patents

Download PDF

Info

Publication number
JP2001523729A5
JP2001523729A5 JP2000521855A JP2000521855A JP2001523729A5 JP 2001523729 A5 JP2001523729 A5 JP 2001523729A5 JP 2000521855 A JP2000521855 A JP 2000521855A JP 2000521855 A JP2000521855 A JP 2000521855A JP 2001523729 A5 JP2001523729 A5 JP 2001523729A5
Authority
JP
Japan
Prior art keywords
immunogen
subunit
ltb
holotoxin
adjuvanted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000521855A
Other languages
English (en)
Japanese (ja)
Other versions
JP4235359B2 (ja
JP2001523729A (ja
Filing date
Publication date
Priority claimed from EP97203671A external-priority patent/EP0919243A1/en
Application filed filed Critical
Publication of JP2001523729A publication Critical patent/JP2001523729A/ja
Publication of JP2001523729A5 publication Critical patent/JP2001523729A5/ja
Application granted granted Critical
Publication of JP4235359B2 publication Critical patent/JP4235359B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000521855A 1997-11-25 1998-11-24 Ltbアジュバントを含むワクチン Expired - Fee Related JP4235359B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97203671A EP0919243A1 (en) 1997-11-25 1997-11-25 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
EP97203671.9 1997-11-25
PCT/EP1998/007553 WO1999026654A1 (en) 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant

Publications (3)

Publication Number Publication Date
JP2001523729A JP2001523729A (ja) 2001-11-27
JP2001523729A5 true JP2001523729A5 (enExample) 2005-12-22
JP4235359B2 JP4235359B2 (ja) 2009-03-11

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000521855A Expired - Fee Related JP4235359B2 (ja) 1997-11-25 1998-11-24 Ltbアジュバントを含むワクチン

Country Status (24)

Country Link
US (1) US6793928B1 (enExample)
EP (2) EP0919243A1 (enExample)
JP (1) JP4235359B2 (enExample)
KR (1) KR100575019B1 (enExample)
CN (1) CN1227032C (enExample)
AT (1) ATE238809T1 (enExample)
AU (1) AU747061C (enExample)
BR (1) BR9815413A (enExample)
CA (1) CA2311492C (enExample)
CZ (1) CZ299770B6 (enExample)
DE (1) DE69814177T2 (enExample)
DK (1) DK1071456T3 (enExample)
ES (1) ES2198089T3 (enExample)
HU (1) HU226214B1 (enExample)
IL (2) IL135905A0 (enExample)
NO (1) NO324690B1 (enExample)
NZ (1) NZ504396A (enExample)
PL (1) PL190925B1 (enExample)
PT (1) PT1071456E (enExample)
RU (1) RU2211050C2 (enExample)
SK (1) SK284572B6 (enExample)
TR (1) TR200001485T2 (enExample)
UA (1) UA72199C2 (enExample)
WO (1) WO1999026654A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
MXPA00010934A (es) * 1998-05-08 2003-07-14 Univ Bristol Vacuna.
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
EP1221970B1 (en) * 1999-10-18 2014-02-19 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stimulating an immune response against infectious agents
RU2223783C1 (ru) * 2002-07-05 2004-02-20 Российская медицинская академия последипломного образования Способ профилактики гриппа и острых респираторных заболеваний у часто болеющих детей
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
EP2076531B1 (en) 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2195466T3 (da) 2007-10-01 2013-01-14 Longhorn Vaccines & Diagnostics Llc Fremgangsmåde til opbevaring af biologiske prøver
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
KR101705268B1 (ko) * 2012-06-20 2017-02-09 고쿠리츠다이가쿠호징 도쿄다이가쿠 점막 면역 부활화제 및 hpv 감염증 치료용 경구 의약 조성물
WO2015089707A1 (zh) 2013-12-16 2015-06-25 财团法人农业科技研究所 生产不耐热肠毒素b亚单位的质粒、方法及其套组
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2019089410A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3965805A4 (en) 2019-05-06 2023-01-25 Synthetic Biologics, Inc. ALKALINE PHOSPHATE BASED ONCOLOGICAL TREATMENTS
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
TWI896302B (zh) * 2024-08-22 2025-09-01 國立清華大學 重組蛋白及其製備方法、包含重組蛋白的疫苗蛋白質佐劑及重組蛋白用於預防呼吸道疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (enExample) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
WO1990006366A1 (en) * 1988-12-07 1990-06-14 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents

Similar Documents

Publication Publication Date Title
JP2001523729A5 (enExample)
Read et al. Effective nasal influenza vaccine delivery using chitosan
AU2004254152B2 (en) Quil a fraction with low toxicity and use thereof
RU2000116260A (ru) Вакцины с адъювантом ltb
DE69519670T2 (de) Mikropartikel mit abgabesystem
WO2001060402A3 (en) Proteosome influenza vaccine
EP0919243A1 (en) Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
JPH10500099A (ja) 非毒性の粘膜アジュバント
RU2005127200A (ru) Менингококковые вакцины для введения через слизистую оболочку
JP2002531415A5 (enExample)
CA2295237A1 (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
EP2281573A3 (en) Influenza vaccine formulations for intradermal delivery
KR970705403A (ko) 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant)
WO2002028427A3 (fr) Composition pharmaceutique pour l'immunisation contre le sida
US20120034305A1 (en) Solid dispersing vaccine composition for oral delivery
EP1024824B1 (en) Solid dispersing vaccine composition for oral delivery
Chand et al. Polyphosphazenes as adjuvants for animal vaccines and other medical applications
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
JP2004504260A5 (enExample)
WO2023172741A3 (en) A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine comprising b- and t-cell antigens, immunogenic composition, and uses thereof
Moschos et al. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
WO1998001558A3 (en) Protein and peptide vaccines for inducing mucosal immunity
de Lorimier et al. Murine antibody response to intranasally administered enterotoxigenic Escherichia coli colonization factor CS6
Lee et al. Mucosal immunity induced by pneumococcal glycoconjugate